Weizmann Institute team IDs a molecule that kills cancer cells; Hyperkalemia investigator reviews data on ZS-9;

> Rony Seger of the Weizmann Institute's Biological Regulation Department and his team say that they have identified a drug molecule that screens off ERK signaling in cancer cells, causing them to die. Significantly, their research indicates that the molecule left healthy cells alone. Release

> At the National Kidney Foundation Spring Clinical Meetings March 25-29 in Dallas, UT Medicine San Antonio renal specialist Wajeh Y. Qunibi, M.D., presented results from two national studies of ZS-9, a new oral drug that has been tested in more than 1,000 patients with high blood potassium. Release

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.